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1. Introduction
While humans have been struggling to search for the best means to control infection to hu‐
mans, infectious agents have been evolving with new means for evading efforts by the body
immune defense to arrest infections. We know that infectious agents escape body defense
mechanisms through evasion of the immune system or development of resistance to drugs
intended to inhibit growth or activity of these organisms. Sometimes using host’s resources
to flourish and unfairly destroying the host and its resources! Malaria parasite for example,
infects human red blood cells, produce clones of itself with different levels of resistance and
immune evasion diversity. The virus e.g. retroviruses, use human genetic materials to repro‐
duce their own nucleic acids (reverse transcription) within infected cells, altering planned
activities, consequently damaging the host cells! This chapter explores step by step why we
can regard infecting organisms as clever than us.
2. Viral infections
Host immune evasion
Existing belief indicates that from primordial soup in which life originated [1], viruses de‐
veloped together with variety of their hosts. In these past millions of years, the hosts have
developed a complex immune defense system against viral infections but the intelligent vi‐
ruses have though developed strategies to evade these host defences and replicate them‐
selves using host’s resources. The host immune response is responsible for defence against
viruses and their consequences. It consists of a complex interwoven series of chemical, cyto‐
kine and cellular interactions that work in synergy in an attempt to remove these invading
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viruses from the body. The outcome of viral infections in an animal is determined by a bal‐
ance between the speed of viral replication and spread, as well as the immune response [2].
Yet, viruses are regarded as important natural means of transferring genes between differ‐
ent species, which increases genetic diversity while in seat to drive evolution [3].
The concern for infections and their evasion strategies arises from the fact that vast of infec‐
tions and all poverty related infections are predominantly found in Africa, for example HIV/
AIDS (Figure 1).
Figure 1. More than two-third of the estimated 39.4 million people living with HIV worldwide are found in Africa.
(Source: UNSAIDS)
The host immunity consists of innate and adaptive immune responses geared at restraining
the viral and other pathogen invasion to keep the host healthy. The innate immune respons‐
es comprise of effector cells that include macrophages, neutrophils, natural killer (NK) cells,
mast cells, basophils and eosinophils. The humoral component of the innate immune re‐
sponse includes the complement cascade, interferon and a host of cytokines and chemokines
associated with inflammation. These cytokines and chemokines interact to attract, activate
and control the function of effector cells. NK cells are prime effector cells of the innate im‐
mune response to virally infected cells and they act by destroying infected cells through re‐
lease of effector granules such as perforins and granzymes. Detection of virally infected cells
and control of activation is achieved through the balance of activating and inhibitory recep‐
tors on the NK cells. All nucleated cells within the body express Major Histocompatibility
Complex (MHC)-1 molecule on their surface. MHC-1 molecules bind to receptors (CD94/
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NKG2A) on the surface of NK cells and act as inhibitors of NK cell activity. If these MHC-1
molecules are not present or reduced in number on a cell (such as virally infected cell), there
is no inhibition of NK cell and the NK cell destroy the infected cell. To counter effect this
action by NK cells, the virus cleverly evade this immune protective response through vari‐
ous ways namely: modification of expression of ligands on the surface of the infected cell
either increased expression of inhibitory ligands, expression of viral mimics of inhibitory li‐
gands or decreased expression of activating ligands, inhibition of cytokines such as Interfer‐
on-γ (IFN-γ) or IL-18, viral molecules that competitively bind IL-18 receptors or disruption
of the release of effector molecules like perforins and granzymes. These potentially cleverly
strategies enable viruses to escape punishment from host defence, including the comple‐
ment system, antibodies, interferon, T-cells, cytokines, and programmed cell death, apopto‐
sis [4,5]. Humans have been doing various researches in attempt to block these evasive
mechanisms by the virus but the virus always plans different means as though fighting
against invading viruses remains to be a vicious cycle.
The remarkable number and the complexities of the virus adaptations to suit the diverse im‐
mune response approach by the host poses a challenge to human intelligence on fighting in‐
fectious agents. It is said that through virus-host interactions at molecular level, interference
occurs through gene regulation that consequently modulates a range of fundamental cellu‐
lar processes [6]. While it is not surprising that the viruses develop strategies to overcome
host defences, the great rapidity with which viruses adapt and replicate within host cells to
survive the complex immune mechanisms with multiple adaptations has given the virus an
evolutional complement. The virus genome is relatively small as compared to most of its
hosts and many viruses produce proteins that act in multiple different ways on different
portions of the immune system. This creates a challenge for which best approach should sci‐
entists use to counter effect these virus strategical intelligence.
Antiviral Resistance
Anti-viral resistance is an additional issue of concern. Like with other infections, drug resist‐
ance to anti-vials and clinical implication has been described [7]. Nevertheless, the manage‐
ment of this drug resistance is suggested to be through optimization of host factors and
drug delivery, selection of alternative therapies based on knowledge of mechanisms of re‐
sistance, and the development of new antivirals. All these are subject to intelligence by the
virus to counter effect, which may be rapid as well! For example, prolonged drug exposure
is said to lead to the selection of resistant strains which normally develop via viral muta‐
tions necessitating a strategical approach to restraint viral infections [8] which may include
testing for resistance to drugs before therapy begins [9]. Proposed ways for possible block‐
ade of immune evasion domains on viruses has been suggested including the suitability of
the therapeutic and vaccine efficacy potential [10] but the constantly dynamic and regularly
changing strategies for evasion by pathogenic viruses remain a critical challenge. Prescrip‐
tions ranging from single to multiple ‘cocktail’ drugs have been currently been given to peo‐
ple with HIV in an attempt to make emergence of resistance less likely. In such situation, the
idea is such that even if a strain evolves resistance to one of the drugs, it will still succumb to
other drugs in the combination. However, the virus has been able to evolve resistance to
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more than one drug, some strains being resistant to all major classes of drugs used to com‐
bat the virus [11]. The virus which can develop resistant to reverse transcriptase (RT) inhibi‐
tors, protease inhibitors, fusion/entry inhibitors, integrase inhibitors as well as multidrug
combinations fielding more than one class into a single product must be far clever than us!
With the frequency of cross-resistance between drugs within a class said to be high, it fur‐
ther efforts to control viral replication more complicated [12-15]. This is because to combat
virus strains from becoming resistant to specific antiretroviral drugs, healthcare providers
have been recommending people infected with HIV to take a combination of highly active
antiretroviral drugs therapy (HAART) to enable viruses resistant to single class of drugs not
to have an escape route. In addition, some antiretroviral drugs have been combined into one
pill, known as a ‘fixed dose combination’ to reduce the number of pills to be taken each day
by the patient. Development of resistance to at least major classes of anti-retroviral drugs is
a blow to the HAART strategy of combining drugs from at least two different antiretroviral
drug classes for the purpose.
The major control in pathogen control is clearing of susceptible strains while maintaining
spread of resistant strains. This is because once there is transmission of drug-resistant strains
[16-18], it becomes difficult to contain the pathogen. Mutations in drug target markers is pri‐
marily important in development of drug resistance as indicated by Clavel and Hance [19]
and genotyping for drug resistance markers by sequencing is a complex technology which
presents a challenge for analysis, interpretation, and reporting [20]. This addresses the felt
difficulties in containing infectious agents like viruses which are very minute with great sur‐
vival strategies. The situation could be of substantial impact in sub-Saharan Africa where re‐
cent report on antiretroviral drugs indicates significant increase in prevalence resistance
over time with possibility of spread of high levels of HIV-1 drug resistance in these re‐
source-limited settings [21]. The findings also caution on possibility of the condition to po‐
tentially compromise the effectiveness of HIV treatment programs. An example of drugs
and mechanisms of action and development of resistance is revealed in Table 1 with special
attention on HIV virus.
Drugs Mechanisms of Action Mechanisms of Resistance
Nucleoside analogues
Zidovudine
Stavudine
Lamivudine
Didanosine
Zalcitabine
Abacavir
Analogues of normal nucleosides
Active as triphosphate derivatives
Incorporated into nascent viral DNA
Prematurely terminate HIV DNA synthesis
Thymidine analogue mutations
promote ATP-mediated and
pyrophosphate-mediated excision
of the incorporated terminator
M184V or Q151M complex
mutations impair
incorporation of nucleoside
analogues
Nucleotide analogues
Tenofovir
Same as nucleoside analogues K65R impairs incorporation of
tenofovir into DNA
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Drugs Mechanisms of Action Mechanisms of Resistance
Thymidine analogue mutations
often associated with cross-
resistance to tenofovir
Nonnucleoside reverse-
transcriptase inhibitors
Nevirapine
Efavirenz
Delavirdine
Bind a hydrophobic pocket of HIV type 1 reverse
transcriptase
Block polymerization of viral DNA
Inactive against HIV type 2
Mutations reduce affinity of the
inhibitors for the enzyme
Single mutations generally
sufficient to induce high level of
resistance
Protease inhibitors
Saquinavir
Ritonavir
Indinavir
Nelfinavir
Amprenavir
Lopinavir
Structure derived from natural peptidic
substrates of the HIV type 1 protease
Bind the active site of the protease
Mutations reduce affinity of the
inhibitors for the enzyme
High-level resistance requires
accumulation of mutations
Fusion inhibitors
Enfuvirtide
36-Amino-acid peptide derived from the HR2
domain of glycoprotein 41
Interferes with glycoprotein 41–dependent
membrane fusion
Mutations affect HR1, a domain of
glycoprotein 41 whose interaction
with HR2 promotes membrane
fusion
Table 1. Antiretroviral Agents Used in the Treatment of HIV InfectionSource: Clavel F, Hance [19].
3. Bacterial infections
Antigenic variation
One of the important characteristics of the host immune response is antigen-specificity
through antibody production. In this context, once the host immune system is exposed to a
certain pathogen, it develops a response that is memorable against that pathogen. Similar
pathogen with similar proteins (immunologically called antigens) will be recognized as soon
as the host encounters same infection. This ability by the host’s immune response to remem‐
ber previously encountered pathogen and act accordingly is termed immunological memo‐
ry. This intelligence by the host’s immune response is however not a big problem to
bacterial pathogens. The surveillance by the immune response against invading infectious
agents can still be escaped by the clever pathogen like bacteria. One way in which an infec‐
tious agent, particularly extracellular pathogens can evade immune surveillance is by alter‐
ing its antigens against which the principal defence is the production of antibodies against
their surface structures. This is called antigenic variation. Antigenic variation can be ach‐
ieved through, existence in a wide variety of antigenic types by many infectious agents. Oth‐
er means include antigenic drift (point mutations in the genes encoding for certain antigenic
proteins) and programmed rearrangements in the DNA of some pathogens. For example
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ability of the enteropathogenic Yersinia enterocolitica to survive and proliferate in host tis‐
sue is said to be favoured by suppression of cytokine response that significantly contributes
to the evasion of antibacterial host defence against the pathogen [22]. We know that the im‐
mune system is highly diverse to counter effect the threats by various antigens from various
pathogens but it seems that when we come to evolution, the pathogens evolve faster than
the hosts! But why and how these pathogens look like they think ahead of higher organisms
(their hosts)? It could mean that as the organism becomes complex the rate of evolution is
slow as compared to lower organisms. It is known that the rate of evolutional change is gov‐
erned by the life span of the species where, short-lived species are capable of changing faster
compared to those with a longer life span [23]. On the other side of the coin floods of anti‐
gens per episode may probably confuse the stringent host’s immune response. Bacterial
pathogens for example, are said to dump more than 200 proteins into human macrophage
cells, the 'effector proteins’ [24]. In addition, these proteins are so similar to the human pro‐
teins enabling them to freely interfere with the body's immune response while protecting
the pathogen. Despite the fact that even short-lived species such as bacteria, which have
generation times measured in minutes, do not manifest noticeable evolutionary changes in a
humans lifetime, in some cases, evolution rates can depend on mutation rates [23]. The
changes that will definitely influence the survival strategy of the pathogen like bacteria in
presence of host like humans and animals.
Figure 2. Global distribution of tuberculosis. In sub-Saharan Africa, TB remains the number one cause of death in HIV/
Aids patients, and those infected with HIV show a much greater incidence of TB than those who are HIV-negative.
WHO statistics do show, however, that HIV-positive adults receiving ARV treatment have substantially lower rates of
TB infection than those who are not receiving treatment. This may not be the case following development of anti-
retroviral drug resistance!Source: http://myfundi.co.za/e/Global_distribution_of_diseases:_TB,_HIV/Aids,_chol‐
era_and_malaria
Drug Resistance
Mimicry allows deadly bacteria to evade host's defense through continued sprouting of anti‐
biotic resistance by simulating human proteins [24]. This process of "molecular mimicry" has
led human bacterial pathogens which were at one time easily treatable with antibiotics to
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recently re-emerge as highly infectious public health threats. This situation has drawn atten‐
tion for increased preparedness for emerging and re-emerging diseases [25]. In this context,
the suggested ‘fit-for purpose’ approaches such as the inter-discipline merging with a focus
on ‘one health’ approach, use of participatory epidemiology and disease surveillance and
mobile technologies may offer opportunity for optimal use of limited resources to improve
early detection, diagnosis and response to disease events which could eventually reduce the
impact of such diseases to animal and human populations.
Antibiotic resistance bears serious importance in public health. In both humans and animals,
drug resistant bacteria have been a threat to health and economy due to costs incurred in an
attempt to contain the disease situation which may finally not work out. This resistance may
be natural or develop after antibiotic use. In bacteria, induction of changes in ability to be‐
come antibiotic resistant is influenced by mutations which could be evolutional. This is de‐
spite mutations seemingly not having major effects on limiting evolution as diversity in
morphological evolution (evolution of physical characteristics) has been found not to corre‐
late well with DNA mutation rates [23]. With mutations, bacteria which were once suscepti‐
ble to certain antibiotics are currently no longer controlled or killed by those antibiotics, the
bacteria being able to survive and even multiply in the presence of a respective antibiotic
agent. We have observed this in chronic diseases such as tuberculosis, bovine mastitis and
many other bacterial diseases. Genome sequencing has indicated a known family of kinases
circulating in modern drug resistant pathogens reflecting the prevalence of resistance even
in microbiomes isolated from human use of antibiotics [26]. Bacterial resistance to formally
useful drugs occur in such ways as preventing the antibiotic from getting to its target
through changing the cell permeability for the drug or use ATP to pump drugs outside the
cell, thus reducing the chances that the drug will kill the bacteria. Other means incudes
changing the structure of the target for the drug such that the antibiotic can no longer recog‐
nize or bind to it. In addition, bacteria may destroy the drug through production of say, be‐
ta-lactamases that directly neutralize penicillin. Acquisition of resistance by bacteria may be
achieved through transformation, transposon and scavenging of DNA remnants from other
degraded bacteria. These all are intelligence by the pathogen that needs no higher organ‐
isms (hosts like human and animals) assistance but own capabilities. One would wonder
where these sorts of intelligence come from.
4. Parasitic infections
An example of well-studied tropical infectious parasite is the malaria parasite, Plasmodium
falciparum. A lot of challenges have been posed to scientific community as regards immune
evasion by the malaria parasite due to its ability to overwhelm the impact of host’s immune
response and through resistance to drugs of choice for the disease. Various researches in im‐
munology have in principle shown parasite evasion of host immunity to be ubiquitous in‐
volving a wide range of molecular mechanisms [27]. Immune evasion generates a large
spectrum of pathogenic effects, such as cytokine blows and inflammation. The relationships
between the benefits of immune evasion and its pathogenic consequences could reflect evo‐
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lutional and ecological host–parasite interactions. Such interactions have impacts on the
dose, parasite virulence, immune defence strategies, immunopathology and host specificity
[27]. Protective immunity to malaria for example is won by the parasite through its strat‐
egies used to evade host immunity, including antigen diversity/polymorphisms, antigen
variation and total immune suppression [28].
Figure 3. a:distribution of parasitic diseases, an example of malaria. See (figure above) the concentration of the dis‐
ease insub-Saharan Africa. Source: http://www.nature.com/nrmicro/journal/v4/n9_supp/fig_tab/nrmi‐
cro1525_F2.html b:Despite the global distribution of malaria, high deaths are concentrated in Africa, south of Sahara
where it also contributes to high deaths. This parasitic disease, despite antigen diversity, it is also resistant to most
antimalarial drugs designed to restrain the disease. Consequently, the disease cause global economic and social bur‐
dens [29] particularly predominating in African countries. Source: http://www.nature.com/nrmicro/journal/v4/
n9_supp/fig_tab/nrmicro1525_F2.html
Evidence from population genomics of the immune evasion (var) genes of Plasmodium falci‐
parum [30] suggests recombination to play a key role in maintaining the extraordinary levels
of polymorphism found in the immune evasion genes. Most malaria vaccine-candidate anti‐
gens have highly polymorphic surface proteins that elicit variant-specific immunity [31]. Nev‐
ertheless, this antigenic diversity is still beaten by an evasive malaria parasite as though no
vaccine yet to arrest malaria troubles in endemic areas. Exploration on evolutional relation‐
ships for the design of vaccines based on ancestral sequences, with the potential for inducing
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cross-protection against a wide range of antigenic variants [32] has been proposed, but the par‐
asite always seems to be ahead of the scientific community. Thus, despite efforts for under‐
standing the  mechanisms and patterns  of  genetic  recombination and sequence variation
designing vaccines that represent the worldwide repertoire of polymorphic malarial surface
antigens may be difficult due to dynamic continuum of antigenic variation in the parasite.
Drug resistance is another way apart from immune evasion that the parasite uses to win the
battle against host efforts to fight parasitic infections. A range of drugs for example has been
used for malaria treatment over decades but have ended disapprovingly through develop‐
ment of drug resistance. Similar strategies have been used by other parasites in animals as
well as in humans. Drug resistance and genetic studies on P. falciparum have revealed a
limited geographical genetic diversity in a genetically homogeneous parasite population
[33]. Studies on competitive facilitation of drug-resistant Plasmodium falciparum malaria
have indicated the most highly resistant parasites to out-compete less fit parasite popula‐
tions [34]. Consequently, these resistant strains overgrow under drug pressure posing a
great threat that at one moment there might be an existence of a parasite population which
is highly resistant to drug use. Systematic mapping of genetic variation in Plasmodium falci‐
parum to locate other loci that can facilitate parasite drug resistance [35] is important. How‐
ever, all these efforts will be of value to the scientific community if we will finally be able to
contain the parasite than it being always a hero.
5. Fungal infections
Under the kingdom of Fungi are many species with a wide spectrum of diseases that can infect
humans and other animals most of which being accidentally originating from exogenous sour‐
ces by inhalation (e.g. Aspergillus spp., Cryptococcus neoformans or endemic mycoses) but al‐
so as commensals of the gastrointestinal tract (e.g. Candida spp.) or reactivation of a latent
infection [36]. Clinical manifestation and severity of fungal infections, including transition
from potentially commensals to infections depends on the patient’s immune response, the
host-pathogen interaction and ability of the infecting pathogenic fungus to evade the host im‐
mune response [37-40]. Like other infections, the immunity to fungal infections comprises of
both innate and adaptive responses. These host defence mechanisms require induction and ac‐
tivation after infection through invariant molecular structures shared by large groups of
pathogens (collectively called pathogen-associated molecular patterns, PAMPs) which are rec‐
ognized by a set of pattern recognition receptors (PRRs) in the host immune defence cells, in‐
cluding Toll-like receptors (TLRs) [41]. However, intelligent is the host’s defence, the fungus
can defend better! Thus the fungus has developed a variety of evasive mechanisms to escape
host defence while nourishing themselves within host’s resources.
Immune evasion in fungal infections is not uncommon phenomenon. A pathogen with a variety
of strategies enabling its effective survival within the host while able to evade immune detection
to overcome the smart host immune response is said to be successful. The well-known strategies
employed by fungal pathogens to evade host defense mechanisms includes shielding of stimu‐
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latory PAMPs, modulation of inflammatory signals, shedding of distraction components, per‐
sistence  in  intracellular  environments  and  complement  evasion  [42].  Among  evasion
mechanisms to overcome both innate and adaptive immunity by some fungal infections is phase
transition through expression of yeast-phase specific genes and alteration of cell wall compo‐
nents [43]. In Candida albicans infection, specific enzyme is secreted to degrade and deactivate a
host antimicrobial peptide involved in the protection of the oral mucosa against the fungus thus
enhancing its transition from commensal to pathogen [44].
Similar to other infections, fungal immune evasion when coupled with resistance to poten‐
tial antifungal drugs poses a setback towards arresting diseases; their clinical and pathologi‐
cal consequences. Further, we have to admit diagnosis, epidemiology and mechanisms of
antifungal drug resistance [45] to be a challenge in control of fungal infections. A recent
study [46] for instance, has revealed geographic variations in fungal species and antifungal
resistance rates distribution among isolates pointing out a focused surveillance on emerging
resistance patterns in Candida infection (see Table 2). The study does not cover African con‐
tinent but should be taken as a warning alarm for the potential risks developing countries
like those in Africa may similarly be facing. Antifungal resistance has also been surveyed in
Aspergillus species using molecular tools showing resistance potential for multiple antifun‐
gal drugs [47]. In the same study, new species were in addition, identified which could re‐
flect emergence of new fungal species potentially resistant to drugs. Importantly, it is a
reflection that screening using advanced tools may help to restrain disease transmission
through procedures such as transplantation and blood transfusion. Surveillance networks
that incorporate sequence-based identification of clinical isolates to determine the species
distribution, the clinical disease and outcome of patients with invasive fungal species have
been suggested [48]. Factors driving fungal composition are primarily global and indoor
fungal composition is again said to be geographically patterned with more diversity ob‐
served in temperate zones than in the tropics [49]. But the proposition should be viewed
with special precaution not to rule out the situation to similarly occur in the tropics. This is
particularly critical as fungi are ubiquitous components of indoor human environments,
with most contact between humans and microbes probable thus raising the possibility of
contribution to spread of resistant strains during disease transmission. The idea is that ap‐
plication of antifungal drugs will definitely kill susceptible strains leaving resistant strains
to prevail and circulate in the community of hosts they infect.
Available reports indicate a change in epidemiology of systemic fungal infections citing the
key elements in selection of appropriate antifungal agent which include; the type of patient
(solid-organ or stem-cell transplant), severity of immunosuppression, history of prolonged
exposure to antifungal drugs, and knowledge of the genera and species of the infecting
pathogen and its typical susceptibility pattern [50]. Canonn et al. [51] pointed out on efflux-
mediated antifungal drug resistance with a list of antifungal drugs, their targets and possi‐
ble resistance mechanisms. The authors finally, suggest among other approaches that
scientists can deploy to identify and possibly design multifunctional drugs that inhibit con‐
ventional targets as well as the transcription factors responsible for the overexpression of ef‐
flux pumps and the pumps themselves. This idea was also previously addressed by Monk
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and Goffeau [52]. But we should bear in mind that despite these all efforts, the microbes,
having no laboratories for designing and formulating mechanisms for survival in the host,
can still generate resistance markers through genetic mutations and other gene rearrange‐
ments. Concerns regarding the development of resistance to even the available few antifun‐
gal drugs have been raised [53] and new diagnostic tools for rapid, sensitive, and specific
detection of fungi in clinical material has been proposed to be a mandatory for effective dis‐
covery and designing of appropriate drugs [54]. But how fast and quick are we ahead of the
‘microbe thinking’? I always think that, if it was learning, then the microbes have been
learning faster than human beings! Who amongst us can agree this view? It is through sur‐
veillance on infections, immunity, chemotherapeutics, evolutional characteristics and differ‐
ences between lower and higher organisms that we can get answers.
Species % of isolates by species and geographic region (nb)
Asia-Pacific (51) Latin America
(348)
Europe (750) North America
(936)
Total (2,085)
C. albicans 56.9 43.6 55.2 43.4 48.41
C. glabrata 13.7 5.2 15.7 23.5 18.0
C. parapsilosis 13.7 25.6 13.7 17.1 17.2
C. tropicalis 11.7 17.0 7.3 10.5 10.5
C. krusei 2.0 1.4 2.5 1.6 1.9
C. lusitaniae 0.0 0.9 1.2 2.2 1.6
C. dubliniensis 0.0 0.3 0.8 1.0 0.8
C. guilliermondii 0.0 1.7 0.1 0.1 0.4
Misc.a 2.0 1.6 1.7 0.6 1.2
Table 2. Species distribution of Candida bloodstream infection isolates across geographic regions out of African
continentsSpecies distribution of Candida bloodstream infection isolates across geographic regions: SENTRY
Surveillance Program, 2008 to 2009. aMiscellaneous species including 6 isolates of C. kefyr, 2 each of C. rugosa, C. sake,
and C. pelliculosa, 3 each of C. famata and C. lipolytica, and 1 each of C. lambica, C. utilis, C. haemulonii, C.
norvegensis, and C. inconspicua.nb: number tested.Source: Pfaller et al. [46].
6. Summary
This chapter has discussed in brief, the human infectious agents, host immune response, im‐
mune evasion and drug resistance to various anti-pathogen drugs. The chapter highlighted
how smart is the host’s immune defence mechanisms against infectious agents and how the
pathogens device mechanisms for escape and survival within host’s territory. The net bal‐
ance between host defence and pathogen defence evasion is the one which determines the
fate of infection to either resolve or develop to clinical disease plus its pathological conse‐
quences. In most cases it seems the pathogen wins the battle due to its always far ahead
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‘thinking’ for counter strategies. It remains a question as to whether the pathogens are clever
than their hosts, including humans or is just a miss by human efforts to capture relevant
pathogenic factors without which the infecting organisms would be harmless. The scientific
community is highly acknowledged for the efforts and a synergistic multi-disciplinary ap‐
proach to control striking infections, particularly those with cross-transmission to animals
other than human beings (zoonotic infections). The concern is that with time, the selected
resistant or immune evasive strains will remain in circulation within human and animal
population making control extremely difficult. Consequently, it raises a worry that probably
higher organisms have fewer chances for successful life in presence of lower organisms. Sev‐
eral efforts in research including experimental, clinical and immunological potential impact
of improved nutrition to specific infections have been in place [54-69]. Despite these efforts,
however, vaccine and drug developments have been made difficult by the tricky survival
strategies by pathogens making improvement in health focusing in nutrition not as good as
might be if the pathogens were not that clever. The remaining challenge is how to bring to‐
gether willing interested partners (stakeholders) for joint efforts in control of diseases. At‐
tention should also be directed to zoonotic infections such as tuberculosis whose resistance
may develop in one species and be detrimental to other species for instance drug resistant
Mycobacterium bovis from cattle infecting humans. The ‘one health’ concept in such circum‐
stances will stand a greater chance of playing a role in limiting transmission of the diseases
across species.
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